Baidu
map

Stroke:血糖调节异常可独立预测缺血性卒中患者死亡风险

2014-04-21 cmt 中国医学论坛报糖尿病手机报

天坛医院王拥军教授领导的一项研究显示,血糖调节异常(IGR)可作为我国缺血性卒中患者1年死亡的独立预测因素。研究者强调,我国缺血性卒中患者应早期筛查IGR。文章3月27日在线发表于《卒中》(Stroke)杂志。 研究入选了2639例中国缺血性卒中患者。随访1年结果显示,伴IGR者死亡率明显高于血糖调节正常者(6.8%对2.1%),但两组患者残疾和卒中复发率相似。进一步分析显示,IGR是缺血性卒中

天坛医院王拥军教授领导的一项研究显示,血糖调节异常(IGR)可作为我国缺血性卒中患者1年死亡的独立预测因素。研究者强调,我国缺血性卒中患者应早期筛查IGR。文章3月27日在线发表于《卒中》(Stroke)杂志。

研究入选了2639例中国缺血性卒中患者。随访1年结果显示,伴IGR者死亡率明显高于血糖调节正常者(6.8%对2.1%),但两组患者残疾和卒中复发率相似。进一步分析显示,IGR是缺血性卒中患者1年死亡的独立预测因素(风险比为3.088)。

原始出处:

Jia Q1, Liu G, Zheng H, Zhao X, Wang C, Wang Y, Liu L, Wang Y; on behalf of the Investigators for the Survey on Abnormal Glucose Regulation in Patients With Acute Stroke Across China.Impaired Glucose Regulation Predicted 1-Year Mortality of Chinese Patients With Ischemic Stroke: Data From Abnormal Glucose Regulation in Patients With Acute Stroke Across China.Stroke. 2014 Mar 27.       

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720019, encodeId=e0321e2001940, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Dec 29 08:29:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805985, encodeId=a5a91805985bc, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jul 25 00:29:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804337, encodeId=a952180433ec0, content=<a href='/topic/show?id=8223e686885' target=_blank style='color:#2F92EE;'>#糖调节异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76868, encryptionId=8223e686885, topicName=糖调节异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Apr 28 17:29:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892607, encodeId=1f04189260ef8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Nov 18 22:29:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010319, encodeId=7d2e201031972, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Oct 30 00:29:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983432, encodeId=a61719834324e, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 04 13:29:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255477, encodeId=faa912554e727, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 23 00:29:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720019, encodeId=e0321e2001940, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Dec 29 08:29:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805985, encodeId=a5a91805985bc, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jul 25 00:29:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804337, encodeId=a952180433ec0, content=<a href='/topic/show?id=8223e686885' target=_blank style='color:#2F92EE;'>#糖调节异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76868, encryptionId=8223e686885, topicName=糖调节异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Apr 28 17:29:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892607, encodeId=1f04189260ef8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Nov 18 22:29:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010319, encodeId=7d2e201031972, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Oct 30 00:29:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983432, encodeId=a61719834324e, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 04 13:29:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255477, encodeId=faa912554e727, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 23 00:29:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720019, encodeId=e0321e2001940, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Dec 29 08:29:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805985, encodeId=a5a91805985bc, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jul 25 00:29:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804337, encodeId=a952180433ec0, content=<a href='/topic/show?id=8223e686885' target=_blank style='color:#2F92EE;'>#糖调节异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76868, encryptionId=8223e686885, topicName=糖调节异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Apr 28 17:29:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892607, encodeId=1f04189260ef8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Nov 18 22:29:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010319, encodeId=7d2e201031972, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Oct 30 00:29:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983432, encodeId=a61719834324e, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 04 13:29:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255477, encodeId=faa912554e727, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 23 00:29:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720019, encodeId=e0321e2001940, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Dec 29 08:29:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805985, encodeId=a5a91805985bc, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jul 25 00:29:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804337, encodeId=a952180433ec0, content=<a href='/topic/show?id=8223e686885' target=_blank style='color:#2F92EE;'>#糖调节异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76868, encryptionId=8223e686885, topicName=糖调节异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Apr 28 17:29:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892607, encodeId=1f04189260ef8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Nov 18 22:29:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010319, encodeId=7d2e201031972, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Oct 30 00:29:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983432, encodeId=a61719834324e, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 04 13:29:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255477, encodeId=faa912554e727, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 23 00:29:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1720019, encodeId=e0321e2001940, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Dec 29 08:29:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805985, encodeId=a5a91805985bc, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jul 25 00:29:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804337, encodeId=a952180433ec0, content=<a href='/topic/show?id=8223e686885' target=_blank style='color:#2F92EE;'>#糖调节异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76868, encryptionId=8223e686885, topicName=糖调节异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Apr 28 17:29:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892607, encodeId=1f04189260ef8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Nov 18 22:29:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010319, encodeId=7d2e201031972, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Oct 30 00:29:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983432, encodeId=a61719834324e, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 04 13:29:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255477, encodeId=faa912554e727, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 23 00:29:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1720019, encodeId=e0321e2001940, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Dec 29 08:29:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805985, encodeId=a5a91805985bc, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jul 25 00:29:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804337, encodeId=a952180433ec0, content=<a href='/topic/show?id=8223e686885' target=_blank style='color:#2F92EE;'>#糖调节异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76868, encryptionId=8223e686885, topicName=糖调节异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Apr 28 17:29:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892607, encodeId=1f04189260ef8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Nov 18 22:29:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010319, encodeId=7d2e201031972, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Oct 30 00:29:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983432, encodeId=a61719834324e, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 04 13:29:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255477, encodeId=faa912554e727, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 23 00:29:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1720019, encodeId=e0321e2001940, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Dec 29 08:29:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805985, encodeId=a5a91805985bc, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jul 25 00:29:00 CST 2014, time=2014-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804337, encodeId=a952180433ec0, content=<a href='/topic/show?id=8223e686885' target=_blank style='color:#2F92EE;'>#糖调节异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76868, encryptionId=8223e686885, topicName=糖调节异常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Apr 28 17:29:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892607, encodeId=1f04189260ef8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Nov 18 22:29:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010319, encodeId=7d2e201031972, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Oct 30 00:29:00 CST 2014, time=2014-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983432, encodeId=a61719834324e, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 04 13:29:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255477, encodeId=faa912554e727, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 23 00:29:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]

相关资讯

不要低估低血糖的风险

抗糖尿病药物:过犹不及 我们在糖尿病上的成功是现代医学发挥其益处最有力的例子之一。这些科学上的进步已经帮助数百万患者活得更长、更健康、更充实。2型糖尿病是最常见的糖尿病,研究表明得到适当照顾的2型糖尿病患者,逐渐有希望与未患病的正常人拥有同样的寿命。 不幸的是,糖尿病已经成为一个非常普遍且具有潜在致命威胁的“现象”,近10%的美国人患有糖尿病。虽然抗糖尿病药物能

Diabetologia:胃束带术后血糖改善或与细胞免疫有关

免疫细胞在2型糖尿病和肥胖特征性炎症小体中的作用正在深入调查研究中。为了探讨胃束带收术后早期葡萄糖代谢变化是否与全身性炎症反应,特别是细胞免疫有关,来自澳大利亚圣云仙医院内分泌科Katherine Samaras教授及其团队进行了一项研究,该研究发现胃束带术后葡萄糖代谢的快速改善与循环中促炎免疫细胞,特别是T淋巴细胞的下降有关。该研究结果发表在2013年12月的《Diabetologia》杂志上。

Diabetes Care :高脂和高蛋白饮食增加血糖波动性

为了确定碳水化合物含量相同的高蛋白(HP)和高脂(HF)饮食对强化胰岛素疗法(IIT)治疗的儿童餐后血糖的影响。来自澳大利亚约翰。亨特儿童医院儿科内分泌和糖尿病科的Smart博士等进行了一项研究,发现高蛋白和高脂饮食增加IIT治疗的青少年的血糖波动性。蛋白和脂肪对于延缓餐后血糖升高具有累加作用,同时蛋白能够减少低血糖的发生。研究结果在线发表于2013年10月29日美国《糖尿

JAMA:GCK突变者血糖高但血管并发症发生率较低

一项英国研究显示,尽管葡萄糖激酶(GCK)突变者自出生后空腹血糖水平即轻度升高,但此人群发生微血管和大血管并发症的几率较低。文章1月15日在线发表于《美国医学会杂志》(JAMA)。 研究纳入99例携带GCK突变基因的受试者、91例无糖尿病无基因突变的对照者和83例早发2型糖尿病患者(诊断糖尿病时年龄为45岁或更小)。结果显示,这三组患者的平均糖化血红蛋白(HbA1c)分别为6.9

Lancet:降低血脂血糖可减少BMI升高所致心脑血管风险

心血管事件是全球主要死因,而体重指数(BMI)升高是心血管疾病的重要危险因素。BMI升高所致心血管风险部分由高血压、高血脂和高血糖介导。现阶段针对体重管理的行为治疗只在短期内有效,大多数体重减轻药物疗效不持久或安全性欠佳,手术也只推荐用于非常肥胖的患者。种种问题导致因BMI升高引起的心血管疾病日益增加,许多国家的超重和肥胖问题也愈演愈烈。 但与肥胖不同,血压和血脂等可以在临床或公共卫生中

Diabetes Care:强化血糖控制可降低手术部位感染发生率

降低外科重症监护病房(ICU)患者手术部位感染(SSI)的最佳围手术期血糖范围仍不清楚。为此,来自日本高知大学医学院的Okabayashi教授及其团队进行了一项研究,试图明确围手术期强化胰岛素治疗(IT)是否可以减少患者手术部位感染发生率。该研究结果在线发表在2014年03月21日的Diabetes Care杂志上。 该研究中,447例外科重症监护病房患者被随机分到接受强化胰岛素治疗(血糖目标范

Baidu
map
Baidu
map
Baidu
map